LivaNova (LIVN) Non-Current Deferred Tax Liability (2015 - 2026)
LivaNova (LIVN) reported Non-Current Deferred Tax Liability of $6.8 million for Q1 2026, down 35.89% on a YoY basis from $10.6 million in Q1 2025, and down 28.97% sequentially from $9.6 million in Q4 2025.
LivaNova (LIVN) Non-Current Deferred Tax Liability (2015 - 2026) Analysis & Trends
LivaNova (LIVN) has 12 years of Non-Current Deferred Tax Liability data on file, last reported at $6.8 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deferred Tax Liability fell 35.89% year-over-year to $6.8 million; the trailing twelve-month figure through Mar 2026 stood at $6.8 million (down 35.89% YoY), and the FY2025 full-year result was $9.6 million, down 85.25% from the prior year.
- Non-Current Deferred Tax Liability eased to $6.8 million in Q1 2026, from $9.6 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $89.2 million in Q4 2022 to a low of $6.5 million in Q3 2022.
- A 5-year average of $20.5 million and a median of $10.1 million in 2025 frame the typical range for Non-Current Deferred Tax Liability.
- Across the five-year window, Non-Current Deferred Tax Liability soared 1054.62% in 2022 and sank 85.25% in 2025, its largest moves.
- Tracing LIVN's Non-Current Deferred Tax Liability over 5 years: stood at $89.2 million in 2022, then plunged by 30.34% to $62.2 million in 2023, then gained by 4.62% to $65.0 million in 2024, then slumped by 85.25% to $9.6 million in 2025, then declined by 28.97% to $6.8 million in 2026.
- Business Quant data shows LIVN's Non-Current Deferred Tax Liability at $6.8 million in Q1 2026, $9.6 million in Q4 2025, and $10.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | LivaNova | 4.30 Bn | 3.76 Bn | 243.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.81 Mn |
| Mar 31, 2026 | 6.81 Mn |
| Dec 31, 2025 | 9.59 Mn |
| Dec 31, 2025 | 9.59 Mn |
| Sep 30, 2025 | 10.10 Mn |
| Sep 30, 2025 | 10.10 Mn |
| Jun 30, 2025 | 11.39 Mn |
| Jun 30, 2025 | 11.39 Mn |
| Mar 31, 2025 | 10.63 Mn |
| Mar 31, 2025 | 10.63 Mn |
| Dec 31, 2024 | 65.03 Mn |
| Dec 31, 2024 | 65.03 Mn |
| Sep 30, 2024 | 11.84 Mn |
| Sep 30, 2024 | 11.84 Mn |
| Jun 30, 2024 | 10.84 Mn |
| Jun 30, 2024 | 10.84 Mn |
| Mar 31, 2024 | 10.97 Mn |
| Mar 31, 2024 | 10.97 Mn |
| Dec 31, 2023 | 62.16 Mn |
| Dec 31, 2023 | 62.16 Mn |